Xinqing Lin

1.1k total citations
65 papers, 585 citations indexed

About

Xinqing Lin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Xinqing Lin has authored 65 papers receiving a total of 585 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 14 papers in Epidemiology. Recurrent topics in Xinqing Lin's work include Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Research Studies (22 papers) and Cancer Immunotherapy and Biomarkers (19 papers). Xinqing Lin is often cited by papers focused on Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Research Studies (22 papers) and Cancer Immunotherapy and Biomarkers (19 papers). Xinqing Lin collaborates with scholars based in China, United States and Japan. Xinqing Lin's co-authors include Chengzhi Zhou, Yinyin Qin, Zhanhong Xie, Xiaohong Xie, Haiyi Deng, Shiyue Li, Ming Liu, Ming Ouyang, Jiexia Zhang and Yong Song and has published in prestigious journals such as Journal of Clinical Oncology, Nanoscale and Cellular and Molecular Life Sciences.

In The Last Decade

Xinqing Lin

58 papers receiving 580 citations

Peers

Xinqing Lin
Solenn Brosseau France
Pamela Biondani Italy
Soo Hee Kim South Korea
Marina Kem United States
Bernadette Reyna Asuncion United States
Chuanhua Zhao China
Amy Meister United States
Hongfei Gao China
Irfan Firdaus United States
Solenn Brosseau France
Xinqing Lin
Citations per year, relative to Xinqing Lin Xinqing Lin (= 1×) peers Solenn Brosseau

Countries citing papers authored by Xinqing Lin

Since Specialization
Citations

This map shows the geographic impact of Xinqing Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinqing Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinqing Lin more than expected).

Fields of papers citing papers by Xinqing Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xinqing Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinqing Lin. The network helps show where Xinqing Lin may publish in the future.

Co-authorship network of co-authors of Xinqing Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Xinqing Lin. A scholar is included among the top collaborators of Xinqing Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xinqing Lin. Xinqing Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Fei, Haiyi Deng, Maolin Zhou, et al.. (2025). Anti-PD-1 exacerbates bleomycin-induced lung injury in mice via Caspase-3/GSDME-mediated pyroptosis. Cell Death and Disease. 16(1). 3–3. 1 indexed citations
2.
Li, Ru, Haiyi Deng, Qingyang Li, et al.. (2024). The prognostic impact of severe grade immune checkpoint inhibitor related pneumonitis in non-small cell lung cancer patients. Frontiers in Oncology. 14. 1372532–1372532. 1 indexed citations
3.
4.
5.
Lin, Xinqing, et al.. (2023). Successful management of Epstein‑Barr virus‑associated severe checkpoint inhibitor‑related pneumonitis: A case report. Experimental and Therapeutic Medicine. 25(5). 222–222. 1 indexed citations
6.
Chen, Ziyao, Xinqing Lin, Zhanhong Xie, et al.. (2023). Characteristics and prognosis of EGFR mutations in small cell lung cancer patients in the NGS era. Clinical & Translational Oncology. 26(2). 434–445. 2 indexed citations
7.
Wang, Fei, Xiaohong Xie, Ting Liu, et al.. (2023). A retrospective real‐world experience of immunotherapy in patients with extensive stage small‐cell lung cancer. Cancer Medicine. 12(14). 14881–14891. 11 indexed citations
8.
9.
Deng, Haiyi, Xinqing Lin, Ziying Lin, et al.. (2023). A Risk-Scoring Model for Severe Checkpoint Inhibitor-Related Pneumonitis: A Case–Control Study. Clinical Drug Investigation. 43(5). 347–357. 7 indexed citations
10.
Yau, Lee‐Fong, Yuanxiang Li, Yangqing Zhan, et al.. (2023). Serum sphingolipids aid in diagnosing adult HIV-negative patients with pulmonary cryptococcosis: a clinical cohort study. Journal of Thoracic Disease. 15(10). 5534–5548. 2 indexed citations
11.
Zhang, Kening, Chengzhi Zhou, Xinqing Lin, et al.. (2022). Treatment response and safety of immunotherapy for advanced non-small cell lung cancer with comorbid chronic obstructive pulmonary disease: a retrospective cohort study. Translational Lung Cancer Research. 11(11). 2306–2317. 11 indexed citations
12.
Lin, Xinqing, Tingting Lü, Haiyi Deng, et al.. (2021). Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases. Journal of Neurology. 269(2). 815–823. 10 indexed citations
13.
Xie, Xiaohong, Xinqing Lin, Ming Liu, et al.. (2020). A first case report of clinical response to targeted therapy in a patient with primary myoepithelial carcinoma of the lung harboring EGFR exon 19 deletion. Diagnostic Pathology. 15(1). 71–71. 3 indexed citations
14.
Xie, Xiaohong, Liqiang Wang, Yinyin Qin, et al.. (2020). Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma. Orphanet Journal of Rare Diseases. 15(1). 183–183. 33 indexed citations
15.
Wang, Fei, Xiaohong Xie, Mengmeng Song, et al.. (2020). Tumor immune microenvironment and mutational analysis of tracheal adenoid cystic carcinoma. Annals of Translational Medicine. 8(12). 750–750. 14 indexed citations
16.
Zhou, Chengzhi, Dehua Zhang, Zhanhong Xie, et al.. (2018). Clinical efficacies of gemcitabine combined with docetaxel single or plus bevacizumab as second-line therapy for malignant pleural mesothelioma. Translational Cancer Research. 7(1). 48–54. 1 indexed citations
17.
18.
Qin, Yinyin, Chengzhi Zhou, Zheng Zhu, et al.. (2017). Case report: dermatomyositis associated with lung cancer with heterogeneous morphology. Journal of Thoracic Disease. 9(12). E1110–E1117. 3 indexed citations
19.
Zhou, Chengzhi, et al.. (2013). Association between MPO 463G>A polymorphism and risk of lung cancer: a meta-analysis. Tumor Biology. 34(6). 3449–3455. 5 indexed citations
20.
Ji, Yanan, et al.. (2012). CYP1A1 MspI polymorphisms and lung cancer risk: An updated meta-analysis involving 20,209 subjects. Cytokine. 59(2). 324–334. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Solenn Brosseau Breakdown of academic impact, for papers by Pamela Biondani Breakdown of academic impact, for papers by Soo Hee Kim Breakdown of academic impact, for papers by Marina Kem Breakdown of academic impact, for papers by Bernadette Reyna Asuncion Breakdown of academic impact, for papers by Chuanhua Zhao Breakdown of academic impact, for papers by Amy Meister Breakdown of academic impact, for papers by Hongfei Gao Breakdown of academic impact, for papers by Irfan Firdaus
Rankless by CCL
2026